Posted by Michael Wonder on 24 Aug 2018
Mallinckrodt and NPXe announce FDA fast track designation for Phase 3 trial of inhaled Xenon gas therapy
23 August 2018 - Drug to be studied for improved functional outcomes and survival rates for patients resuscitated after a cardiac arrest.
Mallinckrodt and NPXe today announced that the United States FDA recently granted fast track designation to NPXe's Phase 3 trial of xenon gas for inhalation in post cardiac arrest patients.
The companies anticipate the trial will commence in the coming months, with the first patients enrolled in the U.S.
